We are live on ! Find out more
NLVP

New Leaf Venture Partners Portfolio holdings

AUM $43M
1-Year Est. Return 25.55%
This Fund
S&P 500
This Quarter Est. Return
+0.31%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$149M
AUM Growth
+$34.1M
Cap. Flow
+$50.7M
Cap. Flow %
33.94%
Top 10 Hldgs %
100%
Holding
16
New
3
Increased
–
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
PDSB icon
PDS Biotechnology
PDSB
+$37.8M
2
DMTX
Dimension Therapeutics, Inc
DMTX
+$26.1M
3
WVE icon
Wave Life Sciences
WVE
+$12.3M

Top Sells

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$5.56M
2
CMRX
Chimerix, Inc.
CMRX
+$4.84M
3
DVAX
Dynavax Technologies
DVAX
+$4.15M
4
DERM
Dermira, Inc.
DERM
+$3M
5
XLRN
Acceleron Pharma
XLRN
+$2.85M

Sector Composition

Rank Sector Weight
1 Healthcare 92.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PDSB icon
1
PDS Biotechnology
PDSB
$43.1M
$29.3M 19.62%
+117,243
New +$37.8M
ARAV
2
DELISTED
Aravive, Inc. Common Stock
ARAV
$25.3M 16.91%
339,871
– –
DMTX
3
DELISTED
Dimension Therapeutics, Inc
DMTX
$23.2M 15.55%
+2,059,283
New +$26.1M
ALDR
4
DELISTED
Alder Biopharmaceuticals
ALDR
$16.5M 11.06%
500,398
-164,385
-25% -$5.56M
OXFD
5
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$15.8M 10.6%
1,377,497
– –
DVAX
6
DELISTED
Dynavax Technologies
DVAX
$13.2M 8.85%
546,998
-165,500
-23% -$4.15M
WVE icon
7
Wave Life Sciences
WVE
$1.2B
$12.5M 8.37%
+784,159
New +$12.3M
DERM
8
DELISTED
Dermira, Inc.
DERM
$6.13M 4.1%
177,022
-104,570
-37% -$3M
MRNS
9
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$5.38M 3.6%
176,143
– –
CMRX
10
DELISTED
Chimerix, Inc.
CMRX
$1.97M 1.32%
220,533
-134,474
-38% -$4.84M
KPTI icon
11
Karyopharm Therapeutics
KPTI
$47.6M
– –
-2,732
Closed -$431K
SAGE
12
DELISTED
Sage Therapeutics
SAGE
– –
-23,829
Closed -$1.01M
CALA
13
DELISTED
Calithera Biosciences, Inc
CALA
– –
-14,979
Closed -$1.63M
XLRN
14
DELISTED
Acceleron Pharma
XLRN
– –
-114,621
Closed -$2.85M
AKAO
15
DELISTED
Achaogen Inc
AKAO
– –
-132,728
Closed -$765K
RLYP
16
DELISTED
RELYPSA INC COM
RLYP
– –
-65,961
Closed -$1.22M

Similar funds

BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

New Leaf Venture Partners's Q4 2015 Portfolio in Review

As of Q4 2015, New Leaf Venture Partners held 16 positions worth $149M, up 30% from $115M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

New Leaf Venture Partners deployed $50.7M of net new capital in Q4 2015, opening 3 new positions. Its largest new stake was PDS Biotechnology: 117,243 shares worth $29.3M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 86% a quarter earlier.

On the sell side, the largest reduction was Alder Biopharmaceuticals, an estimated $5.56M trimmed.

  • New Leaf Venture Partners's largest Q4 2015 buy was PDS Biotechnology: 117,243 shares worth $29.3M.
  • New Leaf Venture Partners's biggest Q4 2015 reduction was Alder Biopharmaceuticals, cutting an estimated $5.56M.
  • New Leaf Venture Partners fully exited Acceleron Pharma in Q4 2015, selling an estimated $2.85M.
  • New Leaf Venture Partners's ten largest holdings make up 100% of its $149M portfolio in Q4 2015.
  • New Leaf Venture Partners opened 3 new positions and closed 6 in Q4 2015.
  • New Leaf Venture Partners's portfolio value rose 30% quarter-over-quarter to $149M.

Based on New Leaf Venture Partners's 13F filing for Q4 2015, filed 16 Feb 2016.